GLP-1 Medications and Diarrhea: Why It Happens and How to Manage It
Diarrhea hits roughly 1 in 3 people on semaglutide and 1 in 5 on tirzepatide. Here's the surprising reason a drug that slows the gut still loosens stools — and how to manage it.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on June 29, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
It seems like a contradiction. GLP-1 medications are famous for slowing the gut to a crawl — that is why constipation is such a common complaint — yet GLP-1 diarrhea is just as frequent, and for some people more disruptive. In the pivotal STEP 1 trial of semaglutide 2.4 mg, 31.5% of participants reported diarrhea, roughly double the 15.9% seen on placebo, making it the second most common side effect after nausea.
Evidence: "The most common adverse events with semaglutide were gastrointestinal: nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (23.4%), each occurring at roughly twice the placebo rate." — Wilding JPH, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183
Diarrhea on a GLP-1 drug is usually mild and self-limiting, but it carries one risk the other GI effects do not: rapid fluid and electrolyte loss. Combined with the appetite suppression that already makes people drink less, that can tip into dehydration faster than most expect. Understanding why a motility-slowing medication still produces loose stools is the key to handling it well.
Why GLP-1 Medications Cause Diarrhea
The constipation-versus-diarrhea paradox dissolves once you separate what these drugs do to the upper gut from what happens further downstream. GLP-1 receptor agonists dramatically slow gastric emptying and upper intestinal transit — that is the well-known braking action behind early satiety and constipation. But several downstream effects pull in the opposite direction, and in many people they win out.
The bile acid connection
The most underappreciated driver is bile acid handling. Normally, bile acids released to digest fat are almost entirely reabsorbed in the small intestine. When transit timing and absorption are disrupted, more bile acid spills into the colon, where it draws in water and stimulates secretion — the textbook mechanism of bile acid diarrhea. GLP-1 receptor activation alters this delicate loop, and the same pathway is now being studied therapeutically in patients who have bile acid diarrhea from other causes.
Evidence: "GLP-1 receptor activation reduces upper gastrointestinal motility and decelerates small intestinal transit time, altering bile acid handling — a mechanism that overlaps directly with the pathophysiology of bile acid diarrhea." — Ellegaard AM, et al. Clinical and Translational Gastroenterology. 2025. DOI: 10.14309/ctg.0000000000000815
Microbiome and dietary shifts
The second driver is everything that changes around the medication. GLP-1 drugs shift the gut microbiome, and rapid changes in bacterial populations frequently loosen stools. At the same time, people eat very differently: smaller meals, more protein, and — crucially — more "diet" foods sweetened with sugar alcohols like sorbitol, xylitol, and erythritol, all of which are osmotic laxatives in their own right. Fatty or greasy meals, which the slowed gut now digests poorly, can trigger urgency and oily stools. None of this is the drug acting alone; it is the drug interacting with a changed diet.
Evidence: "GLP-1 receptor agonists slow gastric emptying and reduce upper gastrointestinal motility; this delay is the dominant mechanism behind the class's gastrointestinal effects and underlies symptoms ranging from early satiety to altered bowel transit." — Jalleh RJ, et al. Journal of Clinical Endocrinology & Metabolism. 2025. DOI: 10.1210/clinem/dgae719
Many people experience both ends of the spectrum at different times — constipated during a dose step, then loose a week later — because these competing mechanisms shift in balance as the gut adapts.
How Common Is It?
Diarrhea consistently ranks as the second or third most common gastrointestinal effect across the major obesity trials, trailing nausea and roughly tracking with constipation. Rates rise with dose, and the pattern differs slightly between the single agonist semaglutide and the dual agonist tirzepatide.
| Medication (trial) | Diarrhea rate | Placebo |
|---|---|---|
| Semaglutide 2.4 mg — Wegovy (STEP 1) | 31.5% | 15.9% |
| Tirzepatide 5–15 mg — Zepbound (SURMOUNT-1) | ~19–23% | 7.3% |
| Tirzepatide vs semaglutide — T2D (SURPASS-2) | 13–16% | 12% (sema) |
Evidence: "Among patients with type 2 diabetes, diarrhea was reported in 13% to 16% of those receiving tirzepatide and in 12% of those receiving semaglutide; gastrointestinal events were mostly mild to moderate and occurred chiefly during dose escalation." — Frías JP, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2107519
In SURMOUNT-1, the large obesity trial of tirzepatide, gastrointestinal events including diarrhea were predominantly mild to moderate and clustered during the titration phase — the same pattern that makes slow, patient dose escalation the single most effective preventive tool.
Evidence: "Gastrointestinal adverse events, including diarrhea, were predominantly mild-to-moderate in severity and occurred primarily during dose escalation rather than at maintenance doses." — Jastreboff AM, et al. New England Journal of Medicine. 2022. DOI: 10.1056/NEJMoa2206038
When It Starts and How Long It Lasts
Diarrhea most often appears within the first days after starting the medication or stepping up to a higher dose, mirroring the timing of nausea. For the majority of people it is transient, easing within one to two weeks as the gut acclimates to the new dose. A minority — particularly those on higher doses or with sensitive bowels at baseline — find it lingers as a background issue that flares after fatty or sugar-alcohol-heavy meals. Because the trigger is so often dietary, persistent diarrhea is frequently fixable by changing what lands on the plate rather than by changing the dose.
If queasiness is part of the picture in those early weeks, our guide to managing GLP-1 nausea covers the titration and meal strategies that calm the whole GI system at once.
How to Manage GLP-1 Diarrhea
Clinical guidance for this drug class treats diarrhea as a stepwise problem: protect hydration first, adjust diet second, and reserve anti-diarrheal medication for episodes that do not settle. Unlike constipation, the priority here is preventing fluid and electrolyte depletion.
Evidence: "For diarrhea, maintaining adequate hydration is the priority; dietary modification and anti-motility agents such as loperamide can be used for persistent symptoms, with attention to electrolyte replacement." — Wharton S, et al. Postgraduate Medicine. 2022. DOI: 10.1080/00325481.2021.2002616
Step 1: Replace fluids and electrolytes
Because appetite suppression already curbs fluid intake, the combination of less drinking and more losing is what makes GLP-1 diarrhea risky. Sip fluids steadily through the day rather than relying on thirst, which is blunted on these medications. Plain water alone is not enough during active diarrhea — sodium and potassium leave with the stool, so an oral rehydration solution or an electrolyte drink helps the water actually stay in the body. Watch for the early warning signs of dehydration: dark urine, dizziness on standing, dry mouth, and fatigue.
Step 2: Adjust what you eat
Diet is where most GLP-1 diarrhea is won or lost. The highest-yield changes are removing the osmotic triggers and easing the digestive load:
- Cut sugar alcohols. Sorbitol, xylitol, erythritol, and maltitol hide in protein bars, "sugar-free" sweets, and diet sodas, and they reliably loosen stools.
- Go easy on fat. Greasy, fried, and very rich meals are poorly handled by the slowed gut and often trigger urgency.
- Lean on soluble fiber. Unlike insoluble fiber, soluble fiber such as psyllium or oats absorbs water and adds form to loose stools. Our overview of fiber supplements for weight loss explains the difference and how to dose them.
- Favor bland, binding foods during a flare — the classic bananas, rice, applesauce, and toast pattern, plus lean protein.
- Limit caffeine and alcohol, both of which speed colonic transit.
Step 3: Medications for persistent diarrhea
When diet and hydration are not enough, a short course of loperamide (Imodium) is the standard rescue for acute, non-bloody diarrhea. For diarrhea that proves to be bile acid–driven and persistent, a bile acid sequestrant such as cholestyramine or colesevelam — taken separated from other medications — can be highly effective, and is worth discussing with a prescriber rather than self-treating indefinitely.
| Strategy | What to do | When to use |
|---|---|---|
| Hydration + electrolytes | Steady sipping; oral rehydration or electrolyte drink | Daily during any active diarrhea |
| Cut sugar alcohols | Avoid sorbitol, xylitol, erythritol, maltitol | First dietary step |
| Reduce dietary fat | Smaller, lower-fat meals | If greasy meals trigger urgency |
| Soluble fiber | Psyllium or oats to add form | Loose, frequent stools |
| Loperamide | Standard dose for acute, non-bloody diarrhea | Short-term rescue |
| Bile acid sequestrant | Cholestyramine/colesevelam, separated from other meds | Persistent, bile acid–type diarrhea (with prescriber) |
Red Flags: When to Seek Care
Most GLP-1 diarrhea is a nuisance, not a danger. But a handful of warning signs warrant prompt medical attention: diarrhea severe enough to cause signs of dehydration (lightheadedness, minimal urination, racing heart), blood or black tarry stools, high fever, or severe abdominal pain — especially pain that bores through to the back, which can signal pancreatitis, a rare but serious complication of this drug class. Diarrhea lasting more than a few days without improvement also deserves a call, both to rule out an unrelated infection such as C. difficile and to prevent the electrolyte disturbances that prolonged losses can cause. People taking oral medications that depend on steady absorption — including some blood pressure drugs and oral contraceptives — should know that significant diarrhea can reduce their effectiveness. For the opposite end of the motility spectrum, see our companion guide on GLP-1 medications and constipation.
Key Takeaways
- Diarrhea affects roughly 31% of people on semaglutide 2.4 mg and about 19–23% on tirzepatide, ranking second only to nausea among GLP-1 side effects.
- The paradox of loose stools on a gut-slowing drug is explained by altered bile acid handling, microbiome shifts, and diet changes — especially sugar alcohols and fatty meals — rather than faster motility alone.
- It usually appears early and fades within one to two weeks at a stable dose, though dietary triggers can make it linger.
- Management is stepwise: protect hydration and electrolytes first, cut sugar alcohols and excess fat next, and use loperamide or a bile acid sequestrant for persistent cases.
- Signs of dehydration, bloody stools, high fever, or severe abdominal pain radiating to the back are red flags that warrant urgent medical care.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515. DOI: 10.1056/NEJMoa2107519
Ellegaard AM, Kårhus ML, Winther-Jensen M, et al. Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach. Clinical and Translational Gastroenterology. 2025;16(3):e00815. DOI: 10.14309/ctg.0000000000000815
Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology & Metabolism. 2025;110(1):1-15. DOI: 10.1210/clinem/dgae719
Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022;134(1):14-19. DOI: 10.1080/00325481.2021.2002616
Last updated: 2026-06-29 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.